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Abstract  
Introduction: Primary adrenal insufficiency (PAI) is a rare but severe and potentially life-
threatening condition. No previous studies have characterized Portuguese patients with PAI. 
Aims: To characterize the clinical presentation, diagnostic workup, treatment and follow-up of 
Portuguese patients with confirmed PAI. 
Methods: This multicentre retrospective study examined PAI patients in 12 Portuguese 
hospitals. 
Results: We investigated 278 patients with PAI (55.8% were females), with a mean age of 
33.6±19.3 years at diagnosis. The most frequent presenting clinical features were asthenia 
(60.1%), mucocutaneous hyperpigmentation (55.0%) and weight loss (43.2%); 29.1% of the 
patients presented with adrenal crisis. Diagnosis was established by high plasma ACTH and low 
serum cortisol in most patients (43.9%). The most common etiology of PAI was autoimmune 
adrenalitis (61.0%). There were 38 idiopathic cases. Autoimmune comorbidities were found in 
70% of the patients, the most frequent being autoimmune thyroiditis (60.7%) and type 1 
diabetes mellitus (17.3%). Seventy-nine percent were treated with hydrocortisone (mean dose 
26.3±8.3 mg/day) mostly in three (57.5%) or two (37.4%) daily doses. The remaining patients 
were treated with prednisolone (10.1%), dexamethasone (6.2%) and methylprednisolone 
(0.7%); 66.2% were also on fludrocortisone (median dose of 100 µg/day). Since diagnosis, 
33.5% of patients were hospitalized for disease decompensation. In the last appointment, 
17.2% of patients had complaints (7.6% asthenia and 6.5% depression) and 9.7% had 
electrolyte disturbances. 
Conclusion: This is the first multicentre Portuguese study regarding PAI. The results emphasize 
the need for standardization in diagnostic tests and aetiological investigation and provide a 
framework for improving treatment. 
 
 




Addison disease (AD) or primary adrenal insufficiency (PAI) is a life-threatening disease 
that results from bilateral destruction or dysfunction of the adrenal cortex (1). PAI is a rare 
disease with a reported prevalence of approximately 100 per million inhabitants in European 
countries. The incidence has been estimated at 4–6 cases per million per year but seems to be 
increasing (2-8).  
Tuberculosis has historically been the predominant cause of AD (9-12), but 
autoimmune adrenalitis is now the most prevalent aetiology (80–90%) in industrialized 
countries (1, 4, 5, 7, 13). Other causes include infectious, genetic, metastatic, haemorrhagic 
and infiltrative disorders, as well as surgery or drugs, but these cases are rare in adult patients.  
Auto-immune adrenalitis is frequently associated with other organ-specific 
autoimmune disorders and type 1 or type 2 autoimmune polyendocrine syndrome (APS-1 and 
APS-2). APS-1 is a very rare monogenic disorder caused by mutations in the autoimmune 
regulator (AIRE) gene and is characterized by the presence of two of the three main 
components: AD, chronic mucocutaneous candidiasis and hypoparathyroidism. The more 
common APS-2 is characterized by two or more concurrent autoimmune endocrinopathies, 
such as AD, autoimmune hypo- or hyperthyroidism, and type 1 diabetes mellitus (DM) (14). 
Isolated PAI and APS-2 share the same pattern of complex inheritance (7). 
To date, no data has been available about the epidemiology, clinical features and 
management of Portuguese patients with PAI. The main objective of this study is to 
characterize the clinical presentation, diagnostic workup, treatment and follow-up of such 
patients. Other objectives of this study are to explore the treatment modalities in this group 
and identify the most prevalent concomitant diseases. 
 
Methods 
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This observational, multicentre, retrospective study investigated patients older than 18 years 
with a diagnosis of PAI followed by Endocrinology in 12 national hospitals (four in Northern 
Portugal, three in Central Portugal, and five in Southern Portugal). Hospitals in the Adrenal 
Tumours Study Group (GET-SR) of the Portuguese Society of Endocrinology were invited to 
participate in the study. Patient selection and data collection occurred between September 
and November 2016.  All patient clinical data was anonymized and analyzed by an 
independent reviewer. Consent has been obtained from each patient after full explanation of 
the purpose and nature of all procedures used. Ethical approval was granted by the Ethics 
Committee of Centro Hospitalar de São João.  
The diagnosis of PAI was verified by review of medical records by 15 endocrinologists 
and endocrinology residents from the 12 Portuguese centres. AD was diagnosed based on one 
of the following criteria: 1) a plasma adrenocorticotropic hormone (ACTH) concentration 
exceeding 66 pmol/L in combination with a low serum cortisol (<5ug/dL) ; 2) an abnormal 
standard dose ACTH-stimulation test (peak plasma cortisol <18ug/dL); 3) characteristic clinical 
signs and symptoms such as hyperpigmentation, salt craving, typical electrolyte disturbances, 
and chronic treatment with glucocorticoids and fludrocortisone in patients who were 
diagnosed decades ago. The diagnosis of autoimmune AD was based on positive 
autoantibodies towards 21-hydroxylase or associated autoimmune diseases.  
Cases with no known cause were classified as idiopathic. Patients were excluded if 
their adrenal insufficiency was deemed to be secondary to adrenalectomy, pituitary surgery, 
or prolonged use of glucocorticoids. Patients who died since diagnosis were also excluded. 
 We studied patient demographic and clinical data, particularly regarding diagnosis, 
aetiology, concomitant autoimmune disorders, family history and replacement regimens, such 
as the type, daily dosage and dose frequency of glucocorticoids, as well as the use of 
mineralocorticoids. We assessed the occurrence of hospitalization due to adrenal crisis 
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through the review of all hospital medical records since the diagnosis. Adrenal crisis (AC) was 
defined as an acute impairment of general health requiring hospital admission and 
administration of intravenous saline and glucocorticoids in patients with AD. Furthermore, 
symptoms and electrolyte disturbances at the last appointment were evaluated. 
A comparative analysis was performed to investigate the type of glucocorticoid 
replacement and aetiology, mean daily hydrocortisone equivalent dose, mean daily 
fludrocortisone dose, occurrence of adrenal crisis and the presence of symptoms or electrolyte 
disturbances. Data were initially collected in an Excel® 2011 database, and statistical analysis 
was performed with SPSS® Statistics V.22. Data are presented as proportions, means (SD), or 
medians (range) for variables that did not conform to a normal distribution. The crude 
incidence rates of hospitalization due to AC were estimated as the number of hospitalization 
cases divided by the total follow-up time, and were reported as number of cases per 100 
patient-years. For independent samples, two-way comparisons for proportions were 
performed using a chi-square test (X²) for categorical variables and a t-test or Mann–Whitney 
U test for continuous variables. Statistical significance was taken as two-tailed at the level of 
0.05. All phases of preparation for the study were in line with the ethical and deontological 




The study included 278 adult patients diagnosed with AD between 1950 and 2016, of 
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At the time of the diagnosis, the most frequently reported symptoms and signs were 
asthenia (60.1%), mucocutaneous hyperpigmentation (55.0%), weight loss (43.2%), 
hypotension (42.8%) and hypoglycaemia (8.6%). Hyponatremia was documented in 36.3% of 
cases, while hyperkalaemia occurred in 25.9%. Adrenal crisis was diagnosed in 29.1% of the 





The diagnoses were established by high ACTH and low serum cortisol in 122 (43.9%) 
patients; by an abnormal standard dose ACTH-stimulation test (peak plasma cortisol <18ug/dL) 
in 39 (14.0%) patients; and by characteristic clinical symptoms/signs and chronic treatment 
with glucocorticoids and fludrocortisone in 48 (17.3%) patients who were diagnosed decades 
ago. These data were missing for 69 (24.8%) patients.  
Data regarding etiological investigation was available in 246 patients. The most 
common causes were autoimmune adrenalitis (61.0%), genetic-related AD (14.2%), and 
infectious adrenalitis (7.3%). Thirty-eight cases (15.4%) were considered idiopathic. We also 
documented three cases secondary to bilateral adrenal haemorrhage and two cases of adrenal 
metastatic infiltration. Fig. 1 summarizes the frequency of different forms of AD diagnosed 
from 1950 to 2016.  
 
Patients with autoimmune AD 
 
Among 150 patients with autoimmune AD, 65.3% were female and the mean age at 
diagnosis was 34.9±15.9 years. The mean age of diagnosis was higher for females, 37.9±15.3 
years than for males, 29.2±15.5 years (p<0.001). 
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Ninety-three percent of the patients had autoantibodies directed against 21-
hydroxylase. Computed tomography (CT) scans of the adrenal glands were performed in 50 
patients, among which adrenal morphology was described as normal in 37 cases, while 13 
patients presented reduced size or volume. 
 
Associated endocrine and autoimmune disorders 
 
Isolated autoimmune AD occurred in 30% of the patients, whereas 70% were 
diagnosed with one or more associated autoimmune endocrinopathies. The most common of 
these were autoimmune thyroiditis (60.7%), type 1 Diabetes Mellitus (17.3%), and pernicious 
anaemia (6.7%), with 103 (68.7%) of the patients meeting the criteria for APS-2. We also found 
two patients with associated chronic mucocutaneous candidiasis and meeting the criteria for 
APS-1. Other recorded comorbidities are presented in Fig. 2.  
 
Patients with genetic forms of AD 
Congenital adrenal hyperplasia (CAH) resulting from 21-hydroxylase deficiency 
occurred in 27 patients (55.6% female), with a median age at onset of 3 (range, 0–30) years. 
The diagnosis of CAH was based on the molecular analysis of CYP21A2 gene. Five patients had 
X-linked adrenoleukodystrophy (ALD), with a median age at diagnosis of 25 (range, 11–28) 
years. Three patients had X-linked congenital adrenal hypoplasia with a mutation of DAX1, 
who were all diagnosed within the first year of life.  
 
Patients with post-infectious AD 
Out of the 18 cases (50% female) of infectious adrenalitis, 17 resulted from 
tuberculosis and one resulted from histoplasmosis. The median age at diagnosis was 50 (range, 
18-69) years. Ten patients had records of radiological studies, of which seven showed an 
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In the 38 cases considered idiopathic, the median age at diagnosis was 41 (range, 5-78) 
years. Only two of these patients had records of anti-adrenal antibodies (negative), and 18 
patients had radiological imaging of the adrenal glands (the adrenals were reduced in 
size/volume with calcifications in five patients and normal in 13 patients). 
 
Treatment and follow-up 
 
All patients received glucocorticoid replacement therapy, 79.1% were treated with 
hydrocortisone, 10.1% with prednisolone, 6.1% with dexamethasone, and 0.7% 
methylprednisolone (missing data=11). The mean daily dose for patients with hydrocortisone 
treatment was 26.3±8.3 mg/day (missing data =1), which was divided into one (3.5%), two 
(37.4%), three (57.5%), or four (0.5%) daily doses (missing data=3). Other glucocorticoid 
replacement doses were recalculated as the hydrocortisone equivalent dose (Table 1). Patients 
receiving hydrocortisone had a significantly higher mean daily hydrocortisone equivalent dose 
than patients receiving prednisolone (mean difference of 4.7±1.6 mg/day; p<0.05) and 
dexamethasone (mean difference of 15.2±2.0 mg/day; p<0.001). Replacement with 
dexamethasone was significantly more frequent among patients with CAH (82.4% vs. 17.6%; 
p<0.001). There were no differences between the other types of glucocorticoid replacement 
and aetiology.  
Mineralocorticoid replacement was utilized by 66.5% of the patients, and the median 
fludrocortisone dose was 100 (range, 25-200) µg/day. The two patients under 
methylprednisolone replacement did not receive mineralocorticoid. The prevalence of 
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fludrocortisone replacement was higher in patients with prednisolone (88.9%) than in patients 
with hydrocortisone (68.9%; p=0.021) or dexamethasone (52.9%; p=0.01), but there were no 
differences regarding daily fludrocortisone dose (p=0.46). The mean hydrocortisone equivalent 
dose was not significantly different in patients with or without mineralocorticoid replacement 
(24.0±8.1 mg/day vs. 25.1±9.3 mg/day; p=0.35).  
Since the diagnosis, 33.5% of patients had been hospitalized due to adrenal crisis. The 
overall incidence of AC was 4.36 (95% CI 3.98-4.74) per 100 patient-years. The incidence rate 
of hospital admission was higher in the group receiving hydrocortisone (4.94, 95% CI 4.51-
5.34) than in the group receiving prednisolone (2.78, 95% CI 1.99-3.56) per 100 patient-years 
(p=0.001). There were no differences between dose of glucocorticoid, mineralocorticoid 
replacement or aetiology and the incidence of hospitalizations. 
At the last appointment, 17.2% of the patients had complaints (missing data=31) with 
most common being asthenia (7.6%) and depression (6.5%), while 9.7% presented electrolyte 
disturbances (missing data=17). No association was found between complaints and the type of 




 We reviewed 278 adult patients with AD followed by endocrinology in 12 Portuguese 
hospitals. To date, this is the only Portuguese cohort of patients with PAI. Several patients may 
be followed in other centres or by other specialties, so we were not able to estimate the 
prevalence of this disease in Portugal. However, considering the dimension and the good 
distribution of patients across the country, we assume that this cohort is representative of the 
Portuguese population with AD.  
Several recent studies have suggested an increasing incidence of the disease in the last 
decades (2-4, 8, 15). In our study, it was not possible to determine the incidence of AD over 
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time, however, in agreement with recent data, we found an increasing relative proportion of 
autoimmune AD cases and a decrease in infectious aetiologies over the last decades (1, 4, 13). 
These findings are consistent with the widespread increase in autoimmune diseases and the 
decline in the prevalence of tuberculosis in industrialized countries (3). In line with the results 
from Lauretta et al., the majority of patients in this cohort were female (5). This difference was 
more evident in patients with autoimmune AD (64.3% vs. 35.7%; p = 0.017). 
 In our cohort only 14% of patients had records of a corticotropin test.  Current 
guidelines by the Endocrine Society suggest that only if a corticotropin test is not feasible 
should the combination of low plasma cortisol and ACTH >2 times the upper reference limit be 
used as a preliminary test for suggesting adrenal insufficiency (16). However, in our study, 
most cases were diagnosed several decades ago when the availability of corticotropin was 
limited.  
The most common aetiology was autoimmune AD, and 68% of this subset of patients 
had other autoimmune endocrinopathy. The most frequent concomitant diseases were 
hypothyroidism, DM, hyperthyroidism and pernicious anaemia, which is in concordance with 
studies from Norway (7), Italy (1), the United Kingdom (UK) (17), Sweden (18) and Poland (19).  
 We found 35 patients with genetic forms of adrenal insufficiency, and CAH was the 
most frequent. CAH is the most common cause of adrenal insufficiency in infancy (20). 
Considering the exclusion of paediatric patients and the possible loss of continuity of 
endocrine specialist care from the paediatric to adult environments, we assume that the real 
number of patients with CAH and probably other genetic forms of AD is underestimated in our 
study. 
 The frequency of idiopathic cases was somewhat higher than that reported in other 
studies (13, 21). Only two patients had records of anti-adrenal antibodies, and 18 had 
radiological studies of the adrenals. Considering the radiological findings in some of the 
patients defined as idiopathic, these may correspond to a fraction of underdiagnosed cases of 
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autoimmune or tuberculosis AD. Current guidelines recommend that the aetiology of PAI be 
determined in all patients. According to the patients’ clinical pictures and family histories, 
aetiologies can be screened using 21-hydroxylase antibodies and the 17-hydroxyprogesterone 
serum level at baseline. If antibodies are negative, a CT scan of the adrenals may reveal 
evidence of adrenal infiltrative processes or metastases, and male patients should be tested 
for adrenoleukodystrophy with plasma levels of very-long-chain fatty acids (16, 22). The high 
number of idiopathic cases in this study likely reflects the incomplete aetiological study of 
some of these patients.   
Current treatment recommendations suggest using short-acting glucocorticoids, 
hydrocortisone (15–25 mg), or cortisone acetate (20 –35 mg) in two or three divided oral 
doses per day to avoid overtreatment and enable a diurnal physiological pattern (22). Our 
study revealed that Portuguese patients primarily use short-acting glucocorticoids, which are 
mostly divided into three daily doses. We found similar data from other European countries in 
the literature (1, 7, 18). The mean daily equivalent hydrocortisone dose found in this study 
(26.3 mg/day) was slightly higher than the recommended dose (16). Lower doses have been 
reported in studies in the UK (24.0 mg/day) and Italy (25.2 mg/day) (17, 21), but the use of 
higher doses was found in a Norwegian study (32.4 mg/day) (7). Furthermore, we found that 
patients receiving long-acting glucocorticoids used a significantly lower mean hydrocortisone 
equivalent dose than patients on conventional hydrocortisone replacement. However, these 
preparations are associated with a non-physiological plasma cortisol profile and may result in 
symptoms of over- or under-substitution, despite optimal dose steroid replacement.  
 Mineralocorticoid replacement therapy with fludrocortisone is recommended in all 
patients with PAI (16). The mineralocorticoid replacement rate found in this study (66.5%) was 
somewhat lower than that reported by other studies. In Swedish and UK cohorts, 89% and 
100% of patients were on fludrocortisone, respectively (17, 18).  
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The incidence rate of hospitalizations due to AC found in this population was lower 
than reported in Dutch (5.2/100 person-year) and German (6.3/100 patient years) patients (23, 
24). However, the exclusion of deaths from the assessment is likely to lead to an 
underestimation of the real incidence of AC in this study, as there is a mortality rate associated 
with AC (25, 26) and moreover some of these events may have occurred outside hospital. The 
higher incidence of AC found in patients receiving hydrocortisone may be related with the 
likelihood that patients on short-acting glucocorticoid replacement therapy have periods of 
relatively profound hypocortisolaemia that may predispose patients to an adrenal crisis (27). 
This finding also emphasizes the importance of patient education concerning glucocorticoid 
adjustments in stressful events and adrenal crisis prevention strategies.  
On the last appointment, 17% of our patients had complaints, and 10% had electrolyte 
disturbances. Unfortunately, it was not possible to evaluate in this study the morbidity and 
mortality associated with AD. There is growing evidence that current replacement regimens 
are associated with a significant reduction in health status and working ability (28, 29). 
Moreover, premature death and increased mortality have been demonstrated among AD 
patients (26). These findings are thought to be due to the non-physiological nature of 
conventional replacement therapy (30). Delayed-release hydrocortisone preparations have 
been introduced with the aim of better mimicking the endogenous circadian cortisol rhythm, 
which have been shown to improve quality of life in patients with AD (31). However, these 
preparations are still not available in Portugal. 
One of the strengths of this study is the inclusion of patients from most tertiary 
centres in the northern, central, and southern regions of Portugal. It is also the first national 
cohort of patients with AD, and it was possible to characterize the clinical presentation, 
diagnosis, treatment, and follow-up of the disease.  
The main limitations of this study stem from its retrospective observational nature in 
which data were collected from medical records by several investigators. We can not draw any 
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conclusions about the real incidence of the disease in our country, as this cohort just includes 
adult patients followed on Endocrinology department. Furthermore, as aforementioned, the 
exclusion of deaths probably leads to an underestimation of the disease and incidence of 
adrenal crisis. 
 
 In conclusion, autoimmune AD is the most frequent aetiology in this population but 
there is still a high prevalence of cases considered idiopathic. This study emphasizes the need 
for standardization in diagnostic tests, aetiological investigation, and the investigation of 
associated autoimmune comorbidities. It is also important to advocate the treatment of these 
patients according to current recommendations and to minimize symptoms associated with 
over- or under-substitution of glucocorticoids and under replacement of mineralocorticoid.  
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Fig.1- Frequency of AD cases according to date of diagnosis and etiology.   
 
Fig. 2 – Frequency of concomitant endocrine and autoimmune diseases in patients with 
autoimmune AD. 
*, other: chronic mucocutaneous candidiasis, hypoparathyroidism, alopecia. 












Doses/day (%) Mineralocorticoid 
therapy 
(%) 
Median daily dose of 
fludrocortisone 
(µg ) 
  1 2 3 4   
Hydrocortisone 79.1%  26.3 ± 8.3 3.7% 37.4%  57.5% 0.5%  68.9% 100 (range 25-200) 
Prednisolone 10.1% 21.6 ± 7.4 100%  - - - 88.9% 100 (range 50-200) 
 
Dexamethasone 6.1%  11.1± 7.4  100%  - - - 52.9% 100 (range 50-150) 
Methylprednisolone 0.7%  20  100%  - - - 0 % - 
Total 100%  24.8 ± 8.9  15.8%  33.1%  45.7% 0.7%  66.5% 100 (range 25-200) 




Fig. 1 – Frequency of AD cases according to date of diagnosis and etiology.  
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Fig. 2 – Frequency of concomitant endocrine and autoimmune diseases in patients with autoimmune 
 AD. *, other: chronic mucocutaneous candidiasis, hypoparathyroidism, alopecia.  
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